BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 1, 2017--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will
present a company overview at the Cowen and Company 37th Annual Health
Care Conference on Wednesday, March 8, 2017, at 10:00 a.m. Eastern Time
and at the Barclays Capital Global Healthcare Conference on Thursday,
March 16, 2017, at 11:15 a.m. Eastern Time.
The live webcasts of the presentations will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
The replays of the webcasts will be available for at least 30 days
following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational biologic product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301005641/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,